Doc Groups Seek To Block CMS Biosimilars Policy Via Congress
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter from six physician organizations to Senate Finance Committee Chairman Hatch says CMS' decision to group multiple biosimilars into a single payment code undermines innovation, science and safety.
You may also be interested in...
Biosimilars Payments In Medicare: CMS Signals Willingness To Change
Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.
Biosimilars Payments In Medicare: CMS Signals Willingness To Change
Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.
Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics
CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.